DGAP-News: Aladdin Healthcare Technologies SE
/ Key phrase(s): Miscellaneous
Aladdin Healthcare Technologies SE approved for Listing on OTCQB in the USA 24.11.2021 / 09:00 The issuer is solely accountable for the content material of this announcement.Aladdin Healthcare Technologies SE approved for Listing on OTCQB in the USA
BERLIN/LONDON November 24, 2021 – Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a number one developer of Artificial Intelligence (AI) based mostly healthcare diagnostics and drug discovery purposes, pronounces that it has gained approval from OTC Markets Group to have the firm’s shares listed on the OTCBQ market. The firm’s shares shall be traded below the image ALDNF. Aladdin has agreed to hitch OTCQB on November 29, 2021.
The OTCQB, additionally known as “The Venture Market,” is the center tier of the over the counter (OTC) market for U.S. shares. The itemizing will enhance the attractiveness of the Aladdin share and facilitate higher consideration from traders inside the world’s largest expertise market, the USA, while additionally permitting overseas traders to take part in the buying and selling of the shares. The current itemizing on the Düsseldorf and the Frankfurt Stock Exchange will proceed. The firm then intends, with additional enlargement, to maneuver as much as OTCQX and over the medium time period to the Nasdaq.
“With the American itemizing, we are actually shifting into the world’s greatest capital market for healthcare expertise taking a decisive step to accompany our quickly rising enterprise. As a number one developer of AI healthcare diagnostics and drug discovery purposes for age-related ailments, we see it as a fantastic alternative to current our enterprise mannequin and its progress prospects to traders who’re interested in revolutionary firms with fast progress potential,” mentioned Wade Menpes-Smith, CEO from Aladdin Healthcare Technologies SE.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a number one developer of AI healthcare diagnostics and drug discovery purposes that may speed up each early stage illness prognosis and the end-to-end drug discovery course of. Aladdin targets aged associated illness together with a major focus on Alzheimer’s illness. Aladdin accomplishes this by collaborating with quite a few companions inside the world healthcare ecosystem to confidentially and securely collect focused knowledge together with, genome, tabular, MRI, PET, cognition and different way of life knowledge. These datasets are then analysed by our award-winning AI crew and used to develop proprietary AI instruments that may help healthcare professionals to extra precisely and effectively diagnose aged associated ailments. This new diagnostic course of will save vital time and prices for healthcare professionals. Additionally, our AI drug discovery platform shall be used to by pharmaceutical Companies to hurry up drug growth, medical trials and predict outcomes extra precisely.
Website Link: www.aladdinid.comGSIN: A12ULLISIN: DE000A12ULL2TICKER SYMBOL: NMI
For additional infoAladdin Healthcare Technologies Ltd.Epworth House, 25 City RoadLondon EC1Y 1AAPhone +44 7714 719696Email: [email protected]
Press contact:CROSS ALLIANCE communication GmbHSara PintoTel.: +49 89 1250 90330Email: [email protected]
24.11.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.The issuer is solely accountable for the content material of this announcement.The DGAP Distribution Services embrace Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.dgap.de
